{"id":"amg-531","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Bone marrow fibrosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AMG 531 mimics the action of endogenous thrombopoietin, a cytokine that regulates megakaryocyte development and platelet production. By activating the TPO receptor (c-Mpl), the drug increases platelet counts in patients with thrombocytopenia. This mechanism allows for sustained elevation of platelet levels without the need for repeated transfusions.","oneSentence":"AMG 531 is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocytes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:12.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic immune thrombocytopenia (ITP)"},{"name":"Thrombocytopenia in patients with chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT07048249","phase":"EARLY_PHASE1","title":"Single Arm Romiplostim to Prevent CIT","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-01-26","conditions":"Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia","enrollment":26},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT07421167","phase":"PHASE2","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)","enrollment":164},{"nctId":"NCT03362177","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-30","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":165},{"nctId":"NCT07400341","phase":"PHASE2","title":"Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-31","conditions":"MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA)","enrollment":66},{"nctId":"NCT07400250","phase":"PHASE2","title":"Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-04-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":28},{"nctId":"NCT07321626","phase":"PHASE1","title":"Romiplostim N01 for Platelet Recovery After Haploidentical HSCT","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment","enrollment":130},{"nctId":"NCT03937154","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2020-02-26","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":145},{"nctId":"NCT07345000","phase":"PHASE3","title":"A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Treatment-naïve Severe Aplastic Anemia","enrollment":210},{"nctId":"NCT07278661","phase":"PHASE2","title":"Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-01-01","conditions":"Chirurgical Intervention, Thrombocytopaenia","enrollment":136},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT07206823","phase":"NA","title":"Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Primacy Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT07214025","phase":"","title":"Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-11-01","conditions":"Romiplostim N01, ITP","enrollment":100},{"nctId":"NCT07185893","phase":"NA","title":"A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jun wang","startDate":"2025-09","conditions":"Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia","enrollment":106},{"nctId":"NCT04870346","phase":"","title":"Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-05-10","conditions":"Aplastic Anemia","enrollment":36},{"nctId":"NCT07162519","phase":"NA","title":"Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-09-20","conditions":"Cytotoxic Drugs, Romiplostim N01, Breast Cancer","enrollment":68},{"nctId":"NCT07128576","phase":"PHASE2","title":"Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-09-15","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT04673266","phase":"PHASE2","title":"Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-14","conditions":"Lymphoma Patients, Thrombocytopenia","enrollment":11},{"nctId":"NCT07063225","phase":"PHASE2","title":"Romiplostim N01 for Chemotherapy-induced Thrombocytopenia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08","conditions":"Chemotherapy-induced Thrombocytopenia, Romiplostim N01","enrollment":50},{"nctId":"NCT07043894","phase":"PHASE2","title":"Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-07-01","conditions":"Solid Tumors, Hematological Tumor, Children","enrollment":50},{"nctId":"NCT05325593","phase":"PHASE3","title":"Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-12-02","conditions":"Primary Immune Thrombocytopenia","enrollment":129},{"nctId":"NCT07003256","phase":"","title":"Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT","status":"ENROLLING_BY_INVITATION","sponsor":"Haikou Affiliated Hospital of Central South University Xiangya School of Medicine","startDate":"2024-09-01","conditions":"Thalassemia in Children","enrollment":30},{"nctId":"NCT06992128","phase":"PHASE2","title":"Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-22","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":129},{"nctId":"NCT04671901","phase":"PHASE2","title":"A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-10","conditions":"Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma","enrollment":2},{"nctId":"NCT06898983","phase":"PHASE2","title":"Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-03-31","conditions":"Cancer Treatment-induced Thrombocytopenia (CTIT)","enrollment":97},{"nctId":"NCT06686927","phase":"PHASE2","title":"Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-20","conditions":"Primary Immune Thrombocytopenia","enrollment":36},{"nctId":"NCT04638829","phase":"PHASE4","title":"Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim","status":"COMPLETED","sponsor":"Sobi, Inc.","startDate":"2021-03-15","conditions":"Immune Thrombocytopenia","enrollment":60},{"nctId":"NCT06759636","phase":"PHASE3","title":"FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-21","conditions":"CTIT: Cancer Therapy Induced Thrombocytopenia","enrollment":88},{"nctId":"NCT02052882","phase":"PHASE2","title":"Study of Romiplostim for Chemotherapy Induced Thrombocytopenia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-01-30","conditions":"Isolated Chemotherapy-induced Thrombocytopenia","enrollment":60},{"nctId":"NCT06613880","phase":"PHASE2","title":"Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-10-24","conditions":"Aplastic Anemia, TPO Receptor Agonists","enrollment":48},{"nctId":"NCT06693791","phase":"PHASE2","title":"Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-12-01","conditions":"Platelet Recovery After Umbilical Cord Blood Transplantation","enrollment":34},{"nctId":"NCT06658834","phase":"PHASE2","title":"A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-01","conditions":"Primary Immune Thrombocytopenia","enrollment":129},{"nctId":"NCT06535685","phase":"PHASE4","title":"A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-02","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT04478227","phase":"EARLY_PHASE1","title":"TPO-Mimetic Use in Children for Hematopoietic Failure","status":"COMPLETED","sponsor":"Anjali Sharathkumar","startDate":"2020-08-18","conditions":"Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia","enrollment":15},{"nctId":"NCT06516484","phase":"PHASE4","title":"Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-07-30","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT02773290","phase":"PHASE2, PHASE3","title":"Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2016-05","conditions":"Aplastic Anemia","enrollment":46},{"nctId":"NCT06497036","phase":"PHASE3","title":"Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geropharm","startDate":"2023-04-04","conditions":"Drug Effect, Safety Issues, Immunogenicity","enrollment":160},{"nctId":"NCT00305435","phase":"PHASE2","title":"Safety Study of AMG 531 in Japanese Subjects With ITP","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-02","conditions":"Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":12},{"nctId":"NCT05492409","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2022-03-28","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":160},{"nctId":"NCT06440824","phase":"PHASE3","title":"A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2024-06-01","conditions":"CTIT-Chemotherapy Induced Thrombocytopenia","enrollment":60},{"nctId":"NCT06408324","phase":"","title":"Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe","status":"COMPLETED","sponsor":"European Research Consortium on ITP","startDate":"2022-11-24","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":275},{"nctId":"NCT02094417","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Korea Co., Ltd.","startDate":"2014-04-14","conditions":"Aplastic Anemia","enrollment":35},{"nctId":"NCT02868060","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Kyowa Kirin China Pharmaceutical Co., Ltd.","startDate":"2015-09","conditions":"Immune Thrombocytopenia (ITP)","enrollment":16},{"nctId":"NCT02868099","phase":"PHASE3","title":"Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Kyowa Kirin China Pharmaceutical Co., Ltd.","startDate":"2015-09","conditions":"Immune Thrombocytopenia","enrollment":203},{"nctId":"NCT05220878","phase":"PHASE3","title":"Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2021-09-09","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":160},{"nctId":"NCT04478123","phase":"PHASE2","title":"Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-07-14","conditions":"Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT06201663","phase":"PHASE3","title":"Romiplostim in Chemotherapy-Induced Thrombocytopenia","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-12-17","conditions":"Chemotherapy-induced Thrombocytopenia, Solid Malignancy","enrollment":30},{"nctId":"NCT06137105","phase":"","title":"Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2023-12-01","conditions":"ITP - Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT05323617","phase":"PHASE2","title":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2023-08-31","conditions":"Severe Aplastic Anemia (SAA)","enrollment":""},{"nctId":"NCT04427306","phase":"PHASE2","title":"Neoadjuvant T-VEC in High Risk Early Melanoma","status":"SUSPENDED","sponsor":"University of California, Davis","startDate":"2020-05-21","conditions":"Melanoma","enrollment":6},{"nctId":"NCT06009497","phase":"PHASE4","title":"Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":"Non Severe Aplastic Anemia","enrollment":44},{"nctId":"NCT02335268","phase":"PHASE2","title":"Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia","status":"COMPLETED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2015-05-21","conditions":"Myelodysplastic Syndromes","enrollment":77},{"nctId":"NCT00117143","phase":"PHASE1, PHASE2","title":"Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-12-02","conditions":"Thrombocytopenic Purpura","enrollment":16},{"nctId":"NCT04933942","phase":"PHASE2","title":"Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2022-09-13","conditions":"First Progression of MGMT Promoter-methylated Glioblastoma","enrollment":""},{"nctId":"NCT05861297","phase":"PHASE4","title":"Immune Thrombocytopenia Management in Adults","status":"UNKNOWN","sponsor":"Nahda University","startDate":"2020-05-05","conditions":"Immune Thrombocytopenia Purpura","enrollment":467},{"nctId":"NCT05652595","phase":"PHASE1","title":"Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2022-06-03","conditions":"Pharmacodynamics, Pharmacokinetics, Bioequivalence","enrollment":56},{"nctId":"NCT04915287","phase":"PHASE4","title":"Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-06-06","conditions":"Thrombocytopenia; Drugs, Chronic Liver Disease","enrollment":476},{"nctId":"NCT00508820","phase":"PHASE3","title":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-02-01","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenic Purpura","enrollment":407},{"nctId":"NCT00603642","phase":"PHASE3","title":"P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-10-01","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":34},{"nctId":"NCT00415532","phase":"PHASE3","title":"Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-01","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":234},{"nctId":"NCT00102336","phase":"PHASE3","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-04-07","conditions":"Thrombocytopenia, Idiopathic Thrombocytopenic Purpura","enrollment":62},{"nctId":"NCT00102323","phase":"PHASE3","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03-29","conditions":"Thrombocytopenia, Idiopathic Thrombocytopenic Purpura","enrollment":63},{"nctId":"NCT00614523","phase":"PHASE2","title":"Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-07-21","conditions":"MDS, Myelodysplastic Syndromes, Thrombocytopenia","enrollment":250},{"nctId":"NCT01143038","phase":"PHASE2","title":"Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-11-30","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":75},{"nctId":"NCT00907478","phase":"PHASE4","title":"Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-08-11","conditions":"Thrombocytopenia, Idiopathic Thrombocytopenic Purpura","enrollment":169},{"nctId":"NCT01516619","phase":"PHASE2","title":"Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"Non-Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT02279173","phase":"PHASE3","title":"Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-12-10","conditions":"Immune Thrombocytopenia","enrollment":203},{"nctId":"NCT04095936","phase":"PHASE2, PHASE3","title":"Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-12-03","conditions":"Aplastic Anemia","enrollment":24},{"nctId":"NCT03957694","phase":"PHASE2, PHASE3","title":"Study of AMG531(Romiplostim) in Patients With Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-04-25","conditions":"Aplastic Anemia","enrollment":17},{"nctId":"NCT00299182","phase":"PHASE1, PHASE2","title":"Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-03","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT02046291","phase":"PHASE1","title":"Safety of Romiplostim (Nplate®) Following UCBT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-04-10","conditions":"Hematologic Malignancies","enrollment":21},{"nctId":"NCT03622931","phase":"PHASE2","title":"Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines","status":"TERMINATED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2014-02-01","conditions":"Ovarian Cancer","enrollment":21},{"nctId":"NCT04350164","phase":"","title":"Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.","status":"COMPLETED","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2012-04-01","conditions":"Wiskott-Aldrich Syndrome","enrollment":67},{"nctId":"NCT04588194","phase":"PHASE2","title":"Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"David Gomez Almaguer","startDate":"2020-11-01","conditions":"Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura","enrollment":12},{"nctId":"NCT02063763","phase":"","title":"TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2014-05-14","conditions":"Adult Patients, Immune Primary Thrombocytopenia, Splenectomy","enrollment":31},{"nctId":"NCT01971684","phase":"","title":"ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-08","conditions":"Immune Thrombocytopenia","enrollment":120},{"nctId":"NCT02760251","phase":"PHASE4","title":"Immunomodulation With Romiplostim in Young Adults With ITP","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-04","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT04371939","phase":"PHASE2","title":"Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-11-05","conditions":"Wiskott-Aldrich Syndrome","enrollment":30},{"nctId":"NCT04289207","phase":"PHASE2","title":"Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2020-03-01","conditions":"Immune Thrombocytopenia","enrollment":55},{"nctId":"NCT00440037","phase":"PHASE2, PHASE3","title":"Open Label Extension Study of AMG 531 in Japanese Subjects With ITP","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-11","conditions":"Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":44},{"nctId":"NCT01071954","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-12-30","conditions":"Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP","enrollment":66},{"nctId":"NCT00111475","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-07-01","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":45},{"nctId":"NCT01443351","phase":"","title":"Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)","status":"WITHDRAWN","sponsor":"Zealand University Hospital","startDate":"2015-03","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":""},{"nctId":"NCT00902018","phase":"PHASE2","title":"Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-01","conditions":"Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT01980030","phase":"PHASE1, PHASE2","title":"Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-11","conditions":"Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":24},{"nctId":"NCT00321711","phase":"PHASE2","title":"Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-10-01","conditions":"MDS, Myelodysplastic Syndromes, Thrombocytopenia","enrollment":69},{"nctId":"NCT01676961","phase":"PHASE2","title":"Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2013-01","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":5},{"nctId":"NCT03515447","phase":"","title":"Romiplostim in Thoracic Transplantation","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2014-05-01","conditions":"Thrombocytopenia","enrollment":30},{"nctId":"NCT02227576","phase":"PHASE2","title":"Prevention of Thrombocytopenia in Glioblastoma Patients","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2014-07-10","conditions":"Thrombocytopenia, Glioblastoma","enrollment":20},{"nctId":"NCT03343847","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2018-01-27","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":""},{"nctId":"NCT00472290","phase":"NA","title":"Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-04-01","conditions":"Hematology, MDS, Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT01236014","phase":"","title":"Indirect Comparison Between Eltrombopag & Romiplostim","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08","conditions":"Thrombocytopaenia","enrollment":1},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT01444417","phase":"PHASE3","title":"Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":62},{"nctId":"NCT01974232","phase":"","title":"A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2012-01","conditions":"Immune Thrombocytopenia","enrollment":33},{"nctId":"NCT02085993","phase":"","title":"Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-07","conditions":"Immune Thrombocytopenic Purpura","enrollment":41},{"nctId":"NCT02338414","phase":"PHASE2","title":"An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-01","conditions":"Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT02090088","phase":"","title":"Nplate® Pregnancy Exposure Registry","status":"TERMINATED","sponsor":"Amgen","startDate":"2009-05","conditions":"Birth Defect, Spontaneous Abortions, Low Birth Weight","enrollment":4},{"nctId":"NCT00515203","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-07","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":22},{"nctId":"NCT00147225","phase":"PHASE1, PHASE2","title":"AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08","conditions":"Solid Tumors, Advanced Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Romiplostim","romiplostim"],"phase":"phase_3","status":"active","brandName":"AMG 531","genericName":"AMG 531","companyName":"Amgen","companyId":"amgen","modality":"Biologic","firstApprovalDate":"","aiSummary":"AMG 531 is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocytes. Used for Chronic immune thrombocytopenia (ITP), Thrombocytopenia in patients with chronic hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}